Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more
Vcanbio Cell & Gene Engineering Corp Ltd (600645) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.56 Billion CNY
Based on the latest financial reports, Vcanbio Cell & Gene Engineering Corp Ltd (600645) has total liabilities worth CN¥1.56 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vcanbio Cell & Gene Engineering Corp Ltd - Total Liabilities Trend (1992–2024)
This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vcanbio Cell & Gene Engineering Corp Ltd Competitors by Total Liabilities
The table below lists competitors of Vcanbio Cell & Gene Engineering Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥2.92 Billion |
|
Polaris Bay Group Co Ltd
SHG:600155
|
China | CN¥38.83 Billion |
|
Foreign Trade Bank of Latin America Inc
NYSE:BLX
|
USA | $10.85 Billion |
|
Hebei Hengshui Laobaigan Liquor Co Ltd
SHG:600559
|
China | CN¥3.54 Billion |
|
Tabcorp Holdings Ltd
AU:TAH
|
Australia | AU$1.87 Billion |
|
Lucid Group Inc
NASDAQ:LCID
|
USA | $7.67 Billion |
Liability Composition Analysis (1992–2024)
This chart breaks down Vcanbio Cell & Gene Engineering Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vcanbio Cell & Gene Engineering Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vcanbio Cell & Gene Engineering Corp Ltd (1992–2024)
The table below shows the annual total liabilities of Vcanbio Cell & Gene Engineering Corp Ltd from 1992 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.59 Billion | -1.42% |
| 2023-12-31 | CN¥1.61 Billion | -1.12% |
| 2022-12-31 | CN¥1.63 Billion | +8.69% |
| 2021-12-31 | CN¥1.50 Billion | +8.96% |
| 2020-12-31 | CN¥1.38 Billion | -3.55% |
| 2019-12-31 | CN¥1.43 Billion | -2.14% |
| 2018-12-31 | CN¥1.46 Billion | +6.84% |
| 2017-12-31 | CN¥1.37 Billion | +9.08% |
| 2016-12-31 | CN¥1.25 Billion | +10.35% |
| 2015-12-31 | CN¥1.13 Billion | -10.01% |
| 2014-12-31 | CN¥1.26 Billion | +52.82% |
| 2013-12-31 | CN¥824.89 Million | -13.34% |
| 2012-12-31 | CN¥951.88 Million | +64.49% |
| 2011-12-31 | CN¥578.70 Million | +9.69% |
| 2010-12-31 | CN¥527.56 Million | +14.51% |
| 2009-12-31 | CN¥460.71 Million | +16.51% |
| 2008-12-31 | CN¥395.43 Million | -1.94% |
| 2007-12-31 | CN¥403.23 Million | +1.99% |
| 2006-12-31 | CN¥395.35 Million | +22.46% |
| 2005-12-31 | CN¥322.85 Million | +29.68% |
| 2004-12-31 | CN¥248.95 Million | -8.16% |
| 2003-12-31 | CN¥271.07 Million | +29.33% |
| 2002-12-31 | CN¥209.59 Million | -42.94% |
| 2001-12-31 | CN¥367.31 Million | +50.29% |
| 2000-12-31 | CN¥244.41 Million | -0.34% |
| 1999-12-31 | CN¥245.24 Million | -4.46% |
| 1998-12-31 | CN¥256.69 Million | -19.66% |
| 1997-12-31 | CN¥319.51 Million | +76.50% |
| 1996-12-31 | CN¥181.03 Million | -3.57% |
| 1995-12-31 | CN¥187.72 Million | +70.80% |
| 1994-12-31 | CN¥109.91 Million | +145.09% |
| 1993-12-31 | CN¥44.85 Million | +24.05% |
| 1992-12-31 | CN¥36.15 Million | -- |